Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
April 20, 2022 07:30 ET
|
Otonomy, Inc.
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability...
Decibel Therapeutics to Participate in Upcoming Investor Conferences
March 22, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
March 18, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research...
As the US Gets Closer to Over-the-Counter Hearing Aids, Experts Urge Consumers to See a Hearing Care Professional First
March 03, 2022 10:11 ET
|
Hearing Industries Association
Washington, D.C., March 03, 2022 (GLOBE NEWSWIRE) -- In recognition of World Hearing Day on March 3, the Hearing Industries Association (HIA) is releasing results of a recent survey of 1,000 adults...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 28, 2022 16:27 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy to Participate in Two Upcoming Investor Conferences
February 28, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
February 25, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
February 17, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
February 16, 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two...
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 16:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...